---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-028106"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:19:46.221354+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gyre subsidiary receives China NMPA IND approval for F230 in pulmonary arterial hypertension

## Summary
- IND approved by CDE of China's NMPA for F230 tablets, a selective endothelin receptor antagonist for PAH.
- F230 originally licensed from Eisai through Gyre's indirect stockholder GNI Group Ltd.
- Preclinical data showed statistically significant reductions in mean pulmonary artery pressure and right ventricular systolic pressure.
- CEO Han Ying stated commitment to advancing F230 through clinical development for PAH; other indications also being explored.

## SEC filing metadata
- accession: 0001140361-24-028106
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/0001140361-24-028106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/ef20030279-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-028106
- JSON: https://secwatch.observer/filing/0001140361-24-028106.json
- Plain text: https://secwatch.observer/filing/0001140361-24-028106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.